BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Given Average Rating of “Buy” by Brokerages

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) have earned a consensus recommendation of “Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $32.20.

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Guggenheim assumed coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $30.00 target price on the stock. HC Wainwright initiated coverage on BlossomHill Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 price target for the company. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price objective on the stock.

Insider Activity

In related news, Director Carl L. Gordon purchased 625,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bihua Chen bought 312,500 shares of the company’s stock in a transaction on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the director directly owned 3,614,034 shares in the company, valued at approximately $57,824,544. This represents a 9.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Trading Up 3.7%

Shares of NASDAQ:BLSM traded up $0.67 during trading on Tuesday, reaching $18.97. 127,422 shares of the stock traded hands, compared to its average volume of 224,464. BlossomHill Therapeutics has a 52-week low of $15.25 and a 52-week high of $20.61.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.